CoChat

Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial

Open access

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

Purpose: The sodium-glucose transporter 2 inhibitor (SGLT2i) empagliflozin may reduce the incidence of obstructive sleep apnea (OSA) in patients with type 2 diabetes (T2D) and cardiovascular (CV) disease. This analysis of VERTIS CV, the CV outcome trial for the SGLT2i ertugliflozin conducted in a similar group of patients, explored the effects of ertugliflozin on reported incident OSA. Methods: In VERTIS CV, patients ≥ 40 years with T2D and atherosclerotic CV disease (ASCVD) were randomized to ertugliflozin 5 or 15 mg or placebo. The primary endpoint was the composite of major adverse CV events. This exploratory analysis evaluated the impact of ertugliflozin (5 and 15 mg pooled) on incident OSA. Patients with prevalent OSA were excluded. Incident OSA events were based on investigator-reported events using the MedDRA SMQ term “sleep apnea syndrome.” A multivariable Cox proportional hazards regression model was constructed to assess the association between ertugliflozin and incident OSA. Results: Of 8246 patients enrolled, 7697 (93.3%) were without baseline OSA (placebo, n = 2561; ertugliflozin, n = 5136; mean age 64.4 years; BMI 31.7 kg/m 2; HbA1c, 8.2%; 69.2% male; 88.3% White). The OSA incidence rate was 1.44 per 1000 person-years versus 2.61 per 1000 person-years among patients treated with ertugliflozin versus placebo, respectively, corresponding to a 48% relative risk reduction (HR 0.52; 95% CI 0.28–0.96; P = 0.04). Conclusions: In VERTIS CV, ertugliflozin reduced by nearly half the incidence of OSA in patients with T2D and ASCVD. These data contribute to the literature that SGLT2is may have a significant beneficial impact on OSA. Trial registration. ClinicalTrials.gov identifier: NCT01986881.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11325-022-02594-2

Cites

Statistics

Figures

Fig. 1 Kaplan–Meier estimates for time to first OSA event on treatment for patients without OSA at baseline. OSA events are based on adverse events that occurred between the date of the first dose of study medication until treatment end plus an additional 14 days. HR, 95% CI, and P value are based on a stratified Cox proportional hazards model that includes categorical terms for treatment, sex, geographical region, baseline BMI, baseline HbA1c, and baseline eGFR, a continuous term for age, and a stratification factor for enrollment cohort. BMI body mass index; CI confidence interval; eGFR estimated glomerular filtration rate; HbA1c glycated hemoglobin; HR hazard ratio; OSA obstructive sleep apnea
Fig. 1 Kaplan–Meier estimates for time to first OSA event on treatment for patients without OSA at baseline. OSA events are based on adverse events that occurred between the date of the first dose of study medication until treatment end plus an additional 14 days. HR, 95% CI, and P value are based on a stratified Cox proportional hazards model that includes categorical terms for treatment, sex, geographical region, baseline BMI, baseline HbA1c, and baseline eGFR, a continuous term for age, and a stratification factor for enrollment cohort. BMI body mass index; CI confidence interval; eGFR estimated glomerular filtration rate; HbA1c glycated hemoglobin; HR hazard ratio; OSA obstructive sleep apneaCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 10 · Cited by 41

Metadata

Authors
Wojeck, B. S., Inzucchi, S. E., Neeland, I. J., Mancuso, J. P., Frederich, R., Masiukiewicz, U., Cater, N. B., McGuire, D. K., Cannon, C. P., & Yaggi, H. K.
Affiliations
  • Yale University (US)
  • University Hospitals of Cleveland (US)
  • Pfizer (United States) (US)
  • Parkland Health & Hospital System (US)
  • Brigham and Women's Hospital (US)
Corresponding author
Wojeck, Brian S.
Venue
Sleep and Breathing
Published
2022-05-20
Volume
27
Issue
2
Pages
669-672
ISSN
  • 1520-9512 (ISSN-L)
  • 1522-1709
OpenAlex
W4280616327
Cited by
41
References
10
Citations by year
2026: 7 · 2025: 8 · 2024: 12 · 2023: 9 · 2022: 4
FWCI
6.11
Type
journal article
Language
en
Open access
Licence
Locations
  • Sleep And Breathing (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Merck Sharp and Dohme
  • Pfizer
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Physiology (medical) › Obstructive Sleep Apnea Research
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
ertugliflozin, obstructive sleep apnea, SGLT2 inhibitors, type 2 diabetes, atherosclerotic cardiovascular disease, major adverse cardiovascular events, drug safety
MeSH terms
Sodium-Glucose Transporter 2 Inhibitors, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Humans, Male, Middle Aged, Bridged Bicyclo Compounds, Heterocyclic, Sleep Apnea, Obstructive

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial. https://app.cochat.ai/papers/10.1007/s11325-022-02594-2
The paper
Wojeck, B. S., Inzucchi, S. E., Neeland, I. J., Mancuso, J. P., Frederich, R., Masiukiewicz, U., Cater, N. B., McGuire, D. K., Cannon, C. P., & Yaggi, H. K. (2023). Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial. Sleep and Breathing. https://doi.org/10.1007/s11325-022-02594-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.